Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v2-FR
Language French French
Date Updated 2020-10-05 2020-09-14
Drug Identification Number 02480271 02480271
Brand name LARTRUVO LARTRUVO
Common or Proper name OLARATUMAB OLARATUMAB
Company Name ELI LILLY CANADA INC ELI LILLY CANADA INC
Ingredients OLARATUMAB OLARATUMAB
Strength(s) 190MG 190MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 1 Vial, 190 MG / 19 ML 1 Vial, 190 MG / 19 ML
ATC code L01XC L01XC
ATC description
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2020-10-22 2020-10-22
Actual discontinuation date 2020-09-25
Remaining supply date 2020-09-25 2020-10-22
Discontinuation status Discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments Lilly Canada’s Customer Response Centre 1-888-545-5972. Lilly Canada’s Customer Response Centre 1-888-545-5972.
Health Canada comments